Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 7 Within- and between-group changes in quality of life over 12 weeks

From: Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

  Baseline Week 12 Within-group mean change over 12 weeksa Between-group mean change over 12 weeksb
Outcome n Mean ± SD n Mean ± SD Mean (95% CI) Mean (95% CI) P
Prostate cancer symptoms (FACT-P)
 EXE 12 95.1 ± 19.1 12 106.3 ± 24.9 11.7 (0.7, 22.8) 18.0 (1.2, 34.9) 0.04
 NoEXE 14 106.1 ± 30.4 14 107.7 ± 30.8 −3.0 (−12.3, 6.2)   
General (FACT-G)
 EXE 12 69.4 ± 14.1 12 78.4 ± 15.4 8.7 (1.3, 16.2) 11.2 (0.1, 22.2) 0.048
 NoEXE 14 83.2 ± 15.5 14 80.6 ± 17.5 −2.5 (−9.2, 4.3)   
Fatigue (BFI)
 EXE 12 4.2 ± 2.4 12 2.5 ± 2.0 −1.1 (−2.3, 0.1) − 0.8 (− 2.6, 1.0) 0.36
 NoEXE 14 3.2 ± 2.9 14 2.6 ± 2.8 −0.2 (−1.4, 0.9)   
Depression (CES-D)
 EXE 12 15.3 ± 9.8 12 11.5 ± 6.5 −2.5 (−6.7, 1.8) −2.8 (−8.9, 3.3) 0.34
 NoEXE 14 12.6 ± 11.2 14 9.3 ± 8.6 −1.5 (−5.5, 2.5)   
  1. Data presented as mean ± standard deviation. P, significance level; EXE, exercise groups (TRAINPRO and TRAIN); NoEXE, non-exercise groups (PRO and STRETCH)
  2. aEXE relative to NoEXE adjusted for baseline values
  3. bEXE relative to NoEXE adjusted for baseline values, protein supplementation, body mass index and number of comorbidities